In conclusion, to the best of our knowledge, this meta-analysis is the largest body of synthesized evidence to date that assesses the outcomes of metformin treatment alone versus combined metformin and PPAR agonists in patients diagnosed with type 2 diabetes. Here, PPARA is linked to type 2 diabetes mellitus.